LifeTime and improving European healthcare through cell-based interceptive medicine - Glial Plasticity
Article Dans Une Revue Nature Année : 2020

LifeTime and improving European healthcare through cell-based interceptive medicine

1 Berlin Institute for Medical Systems Biology
2 Charité - UniversitätsMedizin = Berlin University Medicine
3 BIH - Berlin Institute of Health
4 DZHK - German Center for Cardiovascular Research
5 Institut Curie [Paris]
6 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
7 Department of Human Genetics, University of Leuven, Leuven, Belgium
8 Weizmann Institute of Science [Rehovot, Israël]
9 BIST - Barcelona Institute of Science and Technology
10 CeMM Research Center for Molecular Medicine of the Austrian Academy of Science [Vienna]
11 Medizinische Universität Wien = Medical University of Vienna
12 LBI-RUD - Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases
13 UMCU - University Medical Center [Utrecht]
14 IGH - Institut de génétique humaine
15 ESMO - European Institute of Oncology [Milan]
16 KNAW - Royal Netherlands Academy of Arts and Sciences
17 Oncode Institute [Utrecht]
18 Princess Máxima Center for Pediatric Oncology [Utrecht, Netherlands]
19 UCL - University College of London [London]
20 EMBL - European Molecular Biology Laboratory [Heidelberg]
21 PAN - Polska Akademia Nauk = Polish Academy of Sciences = Académie polonaise des sciences
22 PUT - Poznan University of Technology
23 FMI - Friedrich Miescher Institute for Biomedical Research
24 Unibas - Université de Bâle = University of Basel = Basel Universität
25 MDC - Max Delbrück Center for Molecular Medicine [Berlin]
26 Aarhus University [Aarhus]
27 OeAW - Austrian Academy of Sciences
28 Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ)
29 Karolinska Institutet [Stockholm]
30 Science for Life Laboratory, Stockholm
31 European Bioinformatics Institute [Cambridge, UK]
32 CAM - University of Cambridge [UK]
33 The Wellcome Trust Sanger Institute [Cambridge]
34 UPF - Universitat Pompeu Fabra [Barcelona]
35 ICREA - Institució Catalana de Recerca i Estudis Avançats = Catalan Institution for Research and Advanced Studies
36 Radboud University Medical Center [Nijmegen]
37 Universität Bonn = University of Bonn
38 CBS - Centre de Biochimie Structurale [Montpellier]
39 VIB - Vlaams Instituut voor Biotechnologie [Ghent, Belgique]
40 AOUP - Azienda Ospedale Università di Padova = Hospital-University of Padua
41 Veneto Institute of Oncology IOV-IRCCS [Padua, Italy]
42 HU Berlin - Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin
43 The Babraham Institute [Cambridge, UK]
44 IGF MGX - Institut de Génomique Fonctionnelle - Montpellier GenomiX
Geneviève Almouzni
Giacomo Cavalli
Marcelo Nollmann
Sergio Roman-Roman
  • Fonction : Auteur
Philip Rosenstiel
  • Fonction : Auteur
Joachim Schultze
  • Fonction : Auteur
Oliver Stegle
  • Fonction : Auteur
Amos Tanay
Giuseppe Testa
  • Fonction : Auteur
Dimitris Thanos
  • Fonction : Auteur
Fabian Theis
  • Fonction : Auteur
Maria-Elena Torres-Padilla
  • Fonction : Auteur
Alfonso Valencia
  • Fonction : Auteur
Céline Vallot
Alexander van Oudenaarden
  • Fonction : Auteur
Marie Vidal
  • Fonction : Auteur
Thierry Voet
  • Fonction : Auteur
Monsef Benkirane
  • Fonction : Auteur
  • PersonId : 908767

Résumé

Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade
Fichier principal
Vignette du fichier
LifeTime_white_paper_Revision_ACCEPTED.pdf (1.54 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04023884 , version 1 (18-11-2020)
hal-04023884 , version 2 (14-03-2023)

Licence

Identifiants

Citer

Nikolaus Rajewsky, Geneviève Almouzni, Stanislaw Gorski, Stein Aerts, Ido Amit, et al.. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature, 2020, 587 (7834), pp.377-386. ⟨10.1038/s41586-020-2715-9⟩. ⟨hal-04023884v1⟩
274 Consultations
215 Téléchargements

Altmetric

Partager

More